{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:22:35Z","timestamp":1788452555183,"version":"build-2803163510"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the prediction value of radiomics models based on FDG-PET\/CT for the therapeutic effect in patients with newly-diagnosed multiple myeloma (MM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively reviewed the clinical characteristics and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG-PET\/CT imaging data of 165 MM patients. Randomly divided into a training set (n=133) and a test set (n=32) at a ratio of 8:2. All patients underwent whole-body PET-CT scans within one month prior to the commencement of treatment. Overall response rate was the principal efficacy endpoint, including stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), disease stabilization (SD), and disease progression (PD). Deep response (DR) was defined as sCR, CR, and VGPR, while non-deep response included PR, SD and PD, 74 patients attained DR. Different models involving clinical, radiomics extracted from PET\/CT, and their combination were constructed based on multiple logistic regression and logistic regression machine learning classifier after features selection, respectively. The models predicting performance were evaluated by the area under the ROC curve (AUC), sensitivity, specificity, accuracy, precision, and F1 score. Receiver Operating Characteristic (ROC) curves, decision curves, calibration curves, and DeLong\u2019s test were applied to compare their ability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Gender was the only one of clinical characteristics found to be independent prognosis factor for treatment evaluation, with a p-value of 0.041. The radiomics models outperformed the Clinical model significantly, among which the PET-CT model yielded the best results with the AUC of 0.809. The PET + CT + Clinical model achieved the optimal performance after integrating clinical and radiomic features, with the AUC of 0.813.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The FDG-PET\/CT-based radiomics model, particularly when integrated with clinical features, can more effectively predict deep treatment response in newly diagnosed MM patients, offering significant clinical utility for early treatment stratification and personalized therapeutic guidance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1647730","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T09:36:55Z","timestamp":1764581815000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Application of radiomics model based on FDG-PET\/CT for the assessment of therapeutic effect in patients with newly-diagnosed multiple myeloma"],"prefix":"10.3389","volume":"15","author":[{"given":"Fukai","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangwen","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiyang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaochun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Blade","year":"2014","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN guidelines(R) insights: multiple myeloma, version 3.2022","volume":"20","author":"Anderson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00657-1","article-title":"Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens","volume":"4","author":"Maclachlan","year":"2023","journal-title":"Nat Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Dholaria","year":"2022","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Dholaria","year":"2023","journal-title":"Lancet Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Smith","year":"2021","journal-title":"Lancet Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Gertz","year":"2014","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Madduri","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Moreau","year":"2017","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.12.9653","article-title":"Evolving role of FDG PET\/CT in multiple myeloma imaging and management","volume":"200","author":"Subramaniam","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.03.006","article-title":"Myeloma bone and extra-medullary disease: Role of PET\/CT and other whole-body imaging techniques","volume":"101","author":"Racanelli","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Shaughnessy","year":"2009","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.11.036","article-title":"Radiomics: extracting more information from medical images using advanced feature analysis","volume":"48","author":"Carvalho","year":"2012","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1186\/s12967-023-04437-4","article-title":"Application of radiomics-based multiomics combinations in the tumor microenvironment and cancer prognosis","volume":"21","author":"Luo","year":"2023","journal-title":"J Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Peerlings","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00560-7","article-title":"Predicting cancer outcomes with radiomics and artificial intelligence in radiology","volume":"19","author":"Velcheti","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.981769","article-title":"Differentiation between spinal multiple myeloma and metastases originated from lung using multi-view attention-guided network","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100599","DOI":"10.1016\/j.jbo.2024.100599","article-title":"Radiomics model based on MRI to differentiate spinal multiple myeloma from metastases: A two-center study","volume":"45","author":"Wu","year":"2024","journal-title":"J Bone Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.3390\/jcm12062280","article-title":"Machine learning model based on optimized radiomics feature from (18)F-FDG-PET\/CT and clinical characteristics predicts prognosis of multiple myeloma: A preliminary study","volume":"12","author":"Wang","year":"2023","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"107083","DOI":"10.1016\/j.cmpb.2022.107083","article-title":"Bone marrow segmentation and radiomics analysis of [(18)F]FDG PET\/CT images for measurable residual disease assessment in multiple myeloma","volume":"225","author":"Seiffert","year":"2022","journal-title":"Comput Methods Programs Biomed"},{"key":"B23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12880-023-01033-2","article-title":"(18)F\u2212FDG PET\/CT based radiomics features improve prediction of prognosis: multiple machine learning algorithms and multimodality applications for multiple myeloma","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Med Imaging"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s13246-023-01265-0","article-title":"Radiomics analysis of bone marrow biopsy locations in [(18)F]FDG PET\/CT images for measurable residual disease assessment in multiple myeloma","volume":"46","author":"Seiffert","year":"2023","journal-title":"Phys Eng Sci Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05049-6","article-title":"Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials","volume":"48","author":"Michaud","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001809","article-title":"The added diagnostic value of 18 F-FDG PET\/CT radiomic analysis in multiple myeloma patients with negative visual analysis","volume":"45","author":"Liu","year":"2024","journal-title":"Nucl Med Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Durie","year":"2016","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3","volume":"121","author":"Crowley","year":"2013","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2026027","article-title":"The effect of marital status on the survival of patients with multiple myeloma","volume":"27","author":"Tang","year":"2022","journal-title":"Hematology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-019-0706-9","article-title":"Mortality of lymphoma and myeloma in China, 2004-2017: an observational study","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41408-020-00347-6","article-title":"Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis","volume":"10","author":"Zhang","year":"2020","journal-title":"Blood Cancer J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910615)67:12<3150::AID-CNCR2820671236>3.0.CO;2-U","article-title":"Prognostic factors in multiple myeloma","volume":"67","author":"Lee","year":"1991","journal-title":"Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12875-016-0440-0","article-title":"The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study","volume":"17","author":"Hogg","year":"2016","journal-title":"BMC Fam Pract"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.059246","article-title":"Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response","volume":"97","author":"Heintel","year":"2012","journal-title":"Haematologica"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17237","article-title":"Sex differences in outcomes in multiple myeloma","volume":"192","author":"Jakubowiak","year":"2021","journal-title":"Br J Haematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5630","article-title":"Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era","volume":"12","author":"Liu","year":"2023","journal-title":"Cancer Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3390\/diagnostics13122021","article-title":"Radiomics analysis for multiple myeloma: A systematic review with radiomics quality scoring","volume":"13","author":"Koltsakis","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Moreau","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0023","article-title":"NCCN guidelines\u00ae Insights: multiple myeloma, version 1.2025","volume":"23","author":"Anderson","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112138-20240928-00616","article-title":"Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)","volume":"63","year":"2024","journal-title":"Chin J Internal Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Mateos","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1647730\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T09:36:57Z","timestamp":1764581817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1647730\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":42,"alternative-id":["10.3389\/fonc.2025.1647730"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1647730","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"article-number":"1647730"}}